![]() Blueprint Medicines Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. | ![]() Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. | ![]() Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. | ![]() Ohm Oncology Ohm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds. | ![]() Repare Therapeutics Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells. | ||
Founding Date | Founding Date 2011 | Founding Date 2003 | Founding Date N/A | Founding Date 1998 | Founding Date 2015 | Founding Date 2016 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Private | Type Public |
Tags | ||||||
Locations | Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH | Locations Waltham, US HQ Lawrence, US | Locations Wilmington, US HQ Gaithersburg, US | Locations San Diego, US HQ | Locations Austin, US HQ | Locations Montréal, CA HQ Cambridge, US |
Employees | Employees 6552% increase | Employees 35037% increase | Employees N/A | Employees 373157% increase | Employees 167% decrease | Employees 179 |
Valuation ($) | Valuation ($) 5.3 b | Valuation ($) 2.2 b | Valuation ($) N/A | Valuation ($) 6.4 b | Valuation ($) N/A | Valuation ($) 152.4 m |
Financial | ||||||
Revenue (est.) | Revenue (est.) $249.4m (FY, 2023) | Revenue (est.) $163.4m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $829.3m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $51.1m (FY, 2023) |
Cost of goods | Cost of goods $8.5m (FY, 2023) | Cost of goods $3.7m (FY, 2023) | Cost of goods N/A | Cost of goods $192.4m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $240.8m (FY, 2023) | Gross profit $159.6m (FY, 2023) | Gross profit N/A | Gross profit $636.9m (FY, 2023) | Gross profit N/A | Gross profit $51.1m (FY, 2023) |
Net income | Net income ($507m) (FY, 2023) | Net income ($194.9m) (FY, 2023) | Net income N/A | Net income $281.6m (FY, 2023) | Net income N/A | Net income ($93.8m) (FY, 2023) |
Operating ⚠ | ||||||
Patent Applications | Patent Applications N/A | Patent Applications 49 (Aug, 2017) | Patent Applications N/A | Patent Applications 50 (FY, 2020) | Patent Applications N/A | Patent Applications N/A |
Patents (US) | Patents (US) N/A | Patents (US) 11 (Aug, 2017) | Patents (US) N/A | Patents (US) 43 (FY, 2020) | Patents (US) N/A | Patents (US) N/A |
Funding | ||||||
Total funding raised | Total funding raised $ 1.7b | Total funding raised $ 714m | Total funding raised N/A | Total funding raised $ 171.9m | Total funding raised N/A | Total funding raised $ 150.5m |
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
View companyAstraZeneca United States is a biopharmaceutical company.
View companyHalozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyOhm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds.
View company